AI Nose, Ainos' AI-powered digital nose technology simulates human olfaction by detecting volatile organic compounds ("VOCs"). Currently, AI Nose can detect 22 different gases with a 79% accuracy, proving its broad potential in both medical and industrial markets.
The application of AI-powered electronic nose technology extends beyond industrial automation. In the future, we envision robots equipped with olfactory capabilities collaborating with humans in a broader range of scenarios, creating new value in various fields. These robots will better understand and respond to their surroundings, helping humans improve efficiency in dangerous, complex, or labor-intensive tasks. We believe Ainos' expertise and achievements in AI-powered electronic nose technology will drive a leap forward in robotics, paving the way for a new era of human-robot collaboration.
VELDONA® Low-Dose Oral Interferon Technology: A New Approach to Treating Viral and Immune Diseases
Ainos' VELDONA® low-dose oral interferon technology demonstrates significant potential in treating various viral and immune-related diseases.
-
Innovative Treatments for Viral Diseases: VELDONA® offers a breakthrough treatment for viral diseases such as COVID-19 and influenza by modulating the immune system, inhibiting viral replication, and reducing the severity of illness with fewer side effects.
-
Immune-Related Diseases: Sjögren's Syndrome: VELDONA® has shown promising results in clinical trials for treating Sjögren's syndrome, an autoimmune disease characterized by dry mouth and eyes. By regulating immune responses and reducing inflammation, VELDONA® significantly improves patients' quality of life.
-
Potential in the Veterinary Market: VELDONA® has also shown success in the veterinary field, particularly in treating feline chronic gingivostomatitis ("FCGS"). Clinical trials are already underway in Taiwan, with the potential to penetrate the rapidly growing global pet healthcare market upon success.
Major Breakthrough in HIV-Related Oral Warts Treatment and FDA Orphan Drug Designation
Ainos' VELDONA® treatment has achieved a breakthrough in the treatment of human immunodeficiency virus ("HIV")-related oral warts and has received Orphan Drug Designation from the U.S. Food and Drug Administration ("FDA"). This development is expected to significantly enhance the quality of life for HIV patients.
-
Clinical Progress: Ainos is in the process of initiating clinical trials for HIV-related oral warts. Prior clinical trial results indicate that VELDONA® can significantly reduce the size and number of oral warts while enhancing patients' oral health.
-
Significance of FDA Orphan Drug Designation: This designation strengthens VELDONA®'s market potential as a treatment for a rare disease. It offers market exclusivity, tax incentives, and research and development support, accelerating its global commercialization.
Key Collaborations and Developments in 2023-2024
Since 2023, Ainos formed key partnerships to further drive the application and commercialization of its technologies.
-
Collaboration with a Swiss pharmaceutical company to accelerate the global commercialization of VELDONA® for human pharmaceutical markets.
-
Partnership with Topmed International Biotech to promote VELDONA® pet health supplements, with plans to expand into global markets.
-
Joint development of a VOC sensing platform with Nisshinbo Micro Devices and Taiwan's Inabata Sangyo Co., with applications in telemedicine, automotive, industrial monitoring, and environmental safety, strengthening Ainos' position in the AI-powered electronic nose market.
-
Agreement with Taiwan's Carbon Nano Technology Co. to co-develop VOC and POCT technologies, accelerating the promotion of smart healthcare solutions.
Future Outlook
Ainos has cemented its leadership in the fields of smart healthcare and immunotherapy through its dual innovations: AI-powered electronic nose technology and VELDONA® low-dose oral interferon. With excellent progress in research and development, and ahead-of-schedule project completion, the Company continues to demonstrate its technological prowess.
Moving forward, Ainos plans to expand the application of its technologies, playing a key role in driving global advancements in smart healthcare and industrial automation.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA). The Company's clinical-stage product pipeline includes VELDONA human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform.
The name "Ainos" is a combination of "AI" and "Nose" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https://www.ainos.com.
Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on accesswire.com
